| Dr Uma Narayanasami, MD | |
|
750 Washington St, Nemc Division Of Hematology Oncology, Boston, MA 02111-1526 | |
| (617) 636-5000 | |
| Not Available |
| Full Name | Dr Uma Narayanasami |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 750 Washington St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316990872 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 210562 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emerson Hospital - | W concord, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Uma Narayanasami, MD 750 Washington St, Nemc Division Of Hematology Oncology, Boston, MA 02111-1526 Ph: (617) 636-5000 | Dr Uma Narayanasami, MD 750 Washington St, Nemc Division Of Hematology Oncology, Boston, MA 02111-1526 Ph: (617) 636-5000 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
As millions continue working from home during the pandemic or are required to report to jobs as essential employees, many have raised questions about how these work conditions impact our health - and not just as they relate to COVID-19.
For the third consecutive year, Standard Process Inc.® has been named to INC. magazine's list of the 5,000 fastest growing private companies in America, rising 420 places in rank from last year. Standard Process, a nutritional whole food supplement company in Palmyra, Wis., had revenue growth of 51.2% for the period 2005 through 2008. The magazine also reported that the company had 2008 revenues of $97.6 million and 270 employees.
WHO today said that the emergence of parasites resistant to artemisinin at the Thai-Cambodia border could seriously undermine the success of the global malaria control efforts.
Kiwifruit, cannabis, tongue implants and smartphone apps are among the latest sleep aids in the spotlight at an international sleep conference to be held in Sydney this week.
› Verified 9 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |